JFLLIFE
JFL Life Sciences financials
- Market cap
- ₹35 Cr
- Sector
- Healthcare
What JFL Life Sciences Ltd does
JFL Life Sciences manufactures pharmaceutical formulations at an FDA-approved facility near Ahmedabad, Gujarat. It does not sell under its own brand; instead it sells its products in bulk to pharmaceutical marketers and traders, who route them to end customers, using the same unbranded, bulk-supply model for both domestic and export markets. Domestically it has a PAN-India market presence, and internationally it supplies formulations to developed and developing countries, exporting mainly through merchant exporters to African, Middle Eastern and CIS countries.
- Manufacturing facilities
- 1 (FDA-approved formulation plant near Ahmedabad, Gujarat)
- Product types manufactured
- 4 (dry powder injections, B-Lactam tablets/capsules, general tablets/capsules, ORS)
- Export market presence
- 10 developed and developing countries
- Domestic market coverage
- PAN India
- Export regions
- African, Middle Eastern and CIS countries (via merchant exporters)
- Regulatory registrations abroad
- MOH-registered in Kenya, Nigeria, Yemen, Cambodia & Myanmar; product registrations in Ukraine, Uzbekistan, Kazakhstan
Quarterly results
Q1 FY27: revenue down 4.2%, net profit up 48.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 40 | 21 | 12 | 12 | 30 −24% | 27 +26% | 63 +438% | 11 −4% |
| EBITDA | 2 | 1 | 1 | 2 | 3 +21% | 3 +148% | 4 +154% | 2 +8% |
| Net profit | 1 | 1 | 0 | 1 | 2 +36% | 2 +173% | 2 +1975% | 1 +48% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −19.6% 1Y
1Y: ₹13.25 on 10 Sept 2025 → ₹10.65. High ₹14.7 (23 Dec 2025), low ₹8.55 (30 Mar 2026).
Financials, as filed
Revenue grew 60.2% a year over 1 year, FY25 to FY26. Operating margin narrowed to 8.9%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹82 Cr | ₹131 Cr |
| Operating profit | ₹8 Cr | ₹12 Cr |
| Operating margin | 10.0% | 8.9% |
| Interest | ₹1 Cr | ₹2 Cr |
| Depreciation | ₹1 Cr | ₹1 Cr |
| Net profit | ₹4 Cr | ₹6 Cr |
| Net margin | 5.1% | 4.9% |
| Cash from operations | ₹-4 Cr | ₹-4 Cr |
| Free cash flow | ₹-4 Cr | ₹-8 Cr |
| ROCE | 16.0% | 18.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹1 Cr | ₹8 Cr | ₹11 Cr | ₹11 Cr | ₹33 Cr | ₹33 Cr |
| Reserves | ₹6 Cr | ₹3 Cr | ₹21 Cr | ₹25 Cr | ₹9 Cr | ₹13 Cr |
| Borrowings | ₹17 Cr | ₹16 Cr | ₹7 Cr | ₹6 Cr | ₹11 Cr | ₹22 Cr |
| Other liabilities | ₹5 Cr | ₹21 Cr | ₹10 Cr | ₹15 Cr | ₹32 Cr | ₹39 Cr |
| Total liabilities | ₹29 Cr | ₹48 Cr | ₹49 Cr | ₹57 Cr | ₹86 Cr | ₹106 Cr |
| Fixed assets | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹12 Cr | ₹12 Cr | ₹15 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹23 Cr | ₹41 Cr | ₹42 Cr | ₹44 Cr | ₹74 Cr | ₹92 Cr |
| Total assets | ₹29 Cr | ₹48 Cr | ₹49 Cr | ₹57 Cr | ₹86 Cr | ₹106 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 6% to 943.
- Promoters
- 67.5%
- Public
- 32.5%
Since Jun 2025
- Promoters 0.00 pp
- Public 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '22: Promoters 67.5%, Public 32.5%.Dec '22: Promoters 67.5%, Public 32.5%.Mar '23: Promoters 67.5%, Public 32.5%.Sep '23: Promoters 67.5%, Public 32.5%.Mar '24: Promoters 67.5%, Public 32.5%.Sep '24: Promoters 67.5%, Public 32.5%.Mar '25: Promoters 67.5%, Public 32.5%.Jun '25: Promoters 67.5%, Public 32.5%.Sep '25: Promoters 67.5%, Public 32.5%.Dec '25: Promoters 67.5%, Public 32.5%.Mar '26: Promoters 67.5%, Public 32.5%.Jun '26: Promoters 67.5%, Public 32.5%.
Who is on the register
Named in the Jun 2026 filing
Every holder of JFL Life Sciences Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Smiral Ashwinkumar Patel | 44.33% | unchanged |
| Tejal Smiral Patel | 16.58% | unchanged |
| Smiral Ashwinkumar Patel Huf | 3.98% | unchanged |
| Pratik Rajendrabhai Gandhi | 1.22% | unchanged |
| Ashwinbhai Jivrambhai Patel | 0.89% | unchanged |
| Patel Dakshaben | 0.37% | unchanged |
| Rupesh Kirtibhai Patel | 0.34% | unchanged |
| Ashokkumar Parshottamdas Patel | 0.27% | unchanged |
| Ushaben Ashokkumar Patel | 0.21% | unchanged |
| Artiben Manishkumar Patel | 0.20% | unchanged |
| Shobhnaben Kirtikumar Patel | 0.18% | unchanged |
| Kirtikumar Parshottambhai Patel | 0.12% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹11, this stock must grow earnings at -12% every year for 7 years. Our analysis caps realistic growth at ~53%. At that growth it is worth ₹295 — upside of 2674%.
- Growth the price implies
- -12.5% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 52.3% a year
- net profit, FY25–FY26 · EPS 53.1%
- The gap
- -0.7 pp
- 2674% downside if it only repeats history
Learn to analyse JFL Life Sciences Ltd
Guides on how to read this kind of business and the numbers that matter.